|
시장보고서
상품코드
1874393
히루딘(Hirudin) : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)Hirudin - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 히루딘 시장 규모는 2024년에 42억 2,300만 달러로 추정되며, 2025-2031년의 예측 기간에 CAGR 3.1%로 성장을 지속하여, 2031년까지 52억 1,400만 달러로 확대될 것으로 예측됩니다.
본 보고서는 최근 히루덴에 대한 관세 조정과 국제적인 전략적 대응 조치에 대해 국경 간 산업적 발자취, 자본 배분 패턴, 지역경제의 상호의존성, 공급망 재편 등의 관점에서 종합적인 평가를 제공합니다.
히루딘은 의료용 거머리(Hirudo medicinalis)의 침샘에서 추출한 강력한 항응고 단백질입니다. 그 작용기전은 응고 과정에서 피브리노겐을 피브린으로 전환하는 효소인 트롬빈에 직접 결합하여 혈액 응고를 억제하는 것입니다. 이러한 특성으로 인해 히루진은 특히 혈전 형성 위험이 있는 환자에게 매우 효과적인 항응고제입니다. 생명공학의 발전에 따라 히루딘의 생산은 가자미에서 직접 채취하는 방식에서 실험실에서 재조합 DNA 기술을 이용한 대규모 합성으로 전환되었습니다. 현재 힐진은 주로 심부정맥혈전증(DVT), 폐색전증, 특정 뇌졸중과 같은 혈전성 질환의 치료에 사용되고 있습니다. 헤파린 등 기존 항응고제에 알레르기가 있거나 내성이 있는 환자들에게 효과적인 대체요법으로 여겨지고 있습니다. 수년 동안 히루딘의 응용에 대한 연구가 진행됨에 따라 레피루딘, 데실딘 등 다양한 유도체 및 관련 약물이 개발되어 임상 응용 범위가 확대되었습니다.
힐진 시장 개척은 여러 요인에 의해 추진되고 있습니다. 첫째, 혈전성 질환, 특히 심혈관 질환 환자 및 수술 후 환자의 치료 수요가 전 세계적으로 증가함에 따라 힐진 및 그 유도체에 큰 기회를 제공합니다. 고령화와 혈전 및 혈관 질환의 유병률 증가에 따라 효과적인 항응고제에 대한 수요가 증가하고 있습니다. 다음으로, 힐진의 독특한 작용기전은 특정 병태, 특히 헤파린과 같은 기존 항응고제에 알레르기가 있는 환자의 치료에서 우위를 발휘하여 힐진 제품 시장을 더욱 확장하고 있습니다.
그러나, 힐진 시장에는 도전과 위험도 존재합니다. 생산비용은 여전히 높았고, 특히 바이오기술이 미발달한 초기 단계에서는 보급을 제한하는 요인이었습니다. 또한, 히루딘은 강력한 항응고 작용을 가지고 있지만, 사용 시 출혈 위험을 방지하기 위해 환자의 응고 기능을 주의 깊게 모니터링해야 합니다.
시장 집중도 측면에서 보면, 히루딘 생산 기술이 성숙함에 따라 시장은 소수의 대형 제약회사에 집중되는 경향이 있습니다. 이들 기업은 인수, 연구개발, 특허 기술을 통해 시장 점유율을 유지하고 있습니다. 하류 수요 동향이 다양해지면서 히루덴은 기존의 혈전성 질환 치료뿐만 아니라 다른 응고 장애 및 수술 후 치료에도 적용되고 있습니다. 최근의 기술적 진보로는 유전공학을 이용한 힐도인의 재조합 생산으로 생산 효율의 대폭적인 향상과 비용 절감을 실현하여 향후 힐도인의 용도 확대가 기대되고 있습니다.
이 보고서는 힐루딘 세계 시장에 대해 총 판매량, 매출, 가격, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
이 보고서는 2024년을 기준 연도로 하여 2020-2031년의 과거 데이터와 예측 데이터를 포함하여 판매량(톤)과 매출액(백만 달러)으로 힐진 시장 규모, 추정 및 예측을 제시했습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 위치를 분석하고, 힐진에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다.
시장 세분화
기업별
- Novartis
- Teva Pharmaceuticals
- Pfizer, Inc
- Pentapharm
- DUOPUTAI
- Abbott
- Keyken
- Minapharm
- Salubris Bio
- Hoechst AG
- Ciba-Geigy
- Boehringer Ingelheim
- Sanofi
- Xellia Pharmaceuticals
- Haplogen Pharmaceuticals
- Shenzhen Kangtai Biological
- Dong-A ST
유형별 부문
- 천연 히루딘
- 재조합 히루딘
용도별 부문
- 혈전성 질환
- 종양 질환
- 기타
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Hirudin was estimated to be worth US$ 4223 million in 2024 and is forecast to a readjusted size of US$ 5214 million by 2031 with a CAGR of 3.1% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Hirudin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Hirudin is a potent anticoagulant protein originally derived from the salivary glands of the medicinal leech (Hirudo medicinalis). Its mechanism of action involves directly binding to thrombin, the enzyme responsible for converting fibrinogen into fibrin during the clotting process, thus preventing blood coagulation. This unique property makes hirudin a highly effective anticoagulant, especially in patients at risk of thrombus formation. With the advancement of biotechnology, the production of hirudin has shifted from being sourced directly from leeches to large-scale synthesis through recombinant DNA technology in laboratories. Currently, hirudin is primarily used in the treatment of thrombotic conditions such as deep vein thrombosis (DVT), pulmonary embolism, and certain types of strokes. It is considered an effective alternative for patients who are allergic or intolerant to traditional anticoagulants like heparin. Over the years, with increasing research into hirudin's applications, various derivatives and related drugs, such as lepirudin and desirudin, have been developed, broadening its clinical use.
The market development of hirudin is driven by several factors. Firstly, the growing global demand for the treatment of thrombotic diseases, particularly among cardiovascular patients and post-surgical individuals, presents significant opportunities for hirudin and its derivatives. With the aging population and the increasing prevalence of thrombotic and vascular diseases, there is a rising demand for effective anticoagulants. Secondly, hirudin's unique mechanism of action offers advantages in treating certain conditions, particularly for patients who are allergic to traditional anticoagulants like heparin, further driving the market for hirudin products.
However, the hirudin market faces challenges and risks. The production cost remains high, particularly in the early stages when biotechnology was not fully developed, limiting its widespread use. Additionally, although hirudin has strong anticoagulant effects, its use requires careful monitoring of the patient's coagulation function to prevent the risk of bleeding.
In terms of market concentration, as production technologies for hirudin mature, the market has become more concentrated in the hands of a few large pharmaceutical companies that maintain their market share through acquisitions, research and development, and patented technologies. The downstream demand trend is diversifying, with hirudin finding applications not only in traditional thrombotic disease treatment but also in other coagulation disorders and post-surgical care. Recent technological advances include the recombinant production of hirudin using genetic engineering, which has significantly improved production efficiency and lowered costs, potentially expanding the use of hirudin in the future.
This report aims to provide a comprehensive presentation of the global market for Hirudin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hirudin by region & country, by Type, and by Application.
The Hirudin market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hirudin.
Market Segmentation
By Company
- Novartis
- Teva Pharmaceuticals
- Pfizer, Inc
- Pentapharm
- DUOPUTAI
- Abbott
- Keyken
- Minapharm
- Salubris Bio
- Hoechst AG
- Ciba-Geigy
- Boehringer Ingelheim
- Sanofi
- Xellia Pharmaceuticals
- Haplogen Pharmaceuticals
- Shenzhen Kangtai Biological
- Dong-A ST
Segment by Type
- Natural Hirudin
- Recombinant Hirudin
Segment by Application
- Thrombosis Disease
- Tumor Disease
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hirudin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Hirudin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Hirudin in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Hirudin Product Introduction
- 1.2 Global Hirudin Market Size Forecast
- 1.2.1 Global Hirudin Sales Value (2020-2031)
- 1.2.2 Global Hirudin Sales Volume (2020-2031)
- 1.2.3 Global Hirudin Sales Price (2020-2031)
- 1.3 Hirudin Market Trends & Drivers
- 1.3.1 Hirudin Industry Trends
- 1.3.2 Hirudin Market Drivers & Opportunity
- 1.3.3 Hirudin Market Challenges
- 1.3.4 Hirudin Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Hirudin Players Revenue Ranking (2024)
- 2.2 Global Hirudin Revenue by Company (2020-2025)
- 2.3 Global Hirudin Players Sales Volume Ranking (2024)
- 2.4 Global Hirudin Sales Volume by Company Players (2020-2025)
- 2.5 Global Hirudin Average Price by Company (2020-2025)
- 2.6 Key Manufacturers Hirudin Manufacturing Base and Headquarters
- 2.7 Key Manufacturers Hirudin Product Offered
- 2.8 Key Manufacturers Time to Begin Mass Production of Hirudin
- 2.9 Hirudin Market Competitive Analysis
- 2.9.1 Hirudin Market Concentration Rate (2020-2025)
- 2.9.2 Global 5 and 10 Largest Manufacturers by Hirudin Revenue in 2024
- 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hirudin as of 2024)
- 2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Natural Hirudin
- 3.1.2 Recombinant Hirudin
- 3.2 Global Hirudin Sales Value by Type
- 3.2.1 Global Hirudin Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Hirudin Sales Value, by Type (2020-2031)
- 3.2.3 Global Hirudin Sales Value, by Type (%) (2020-2031)
- 3.3 Global Hirudin Sales Volume by Type
- 3.3.1 Global Hirudin Sales Volume by Type (2020 VS 2024 VS 2031)
- 3.3.2 Global Hirudin Sales Volume, by Type (2020-2031)
- 3.3.3 Global Hirudin Sales Volume, by Type (%) (2020-2031)
- 3.4 Global Hirudin Average Price by Type (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Thrombosis Disease
- 4.1.2 Tumor Disease
- 4.1.3 Others
- 4.2 Global Hirudin Sales Value by Application
- 4.2.1 Global Hirudin Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Hirudin Sales Value, by Application (2020-2031)
- 4.2.3 Global Hirudin Sales Value, by Application (%) (2020-2031)
- 4.3 Global Hirudin Sales Volume by Application
- 4.3.1 Global Hirudin Sales Volume by Application (2020 VS 2024 VS 2031)
- 4.3.2 Global Hirudin Sales Volume, by Application (2020-2031)
- 4.3.3 Global Hirudin Sales Volume, by Application (%) (2020-2031)
- 4.4 Global Hirudin Average Price by Application (2020-2031)
5 Segmentation by Region
- 5.1 Global Hirudin Sales Value by Region
- 5.1.1 Global Hirudin Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Hirudin Sales Value by Region (2020-2025)
- 5.1.3 Global Hirudin Sales Value by Region (2026-2031)
- 5.1.4 Global Hirudin Sales Value by Region (%), (2020-2031)
- 5.2 Global Hirudin Sales Volume by Region
- 5.2.1 Global Hirudin Sales Volume by Region: 2020 VS 2024 VS 2031
- 5.2.2 Global Hirudin Sales Volume by Region (2020-2025)
- 5.2.3 Global Hirudin Sales Volume by Region (2026-2031)
- 5.2.4 Global Hirudin Sales Volume by Region (%), (2020-2031)
- 5.3 Global Hirudin Average Price by Region (2020-2031)
- 5.4 North America
- 5.4.1 North America Hirudin Sales Value, 2020-2031
- 5.4.2 North America Hirudin Sales Value by Country (%), 2024 VS 2031
- 5.5 Europe
- 5.5.1 Europe Hirudin Sales Value, 2020-2031
- 5.5.2 Europe Hirudin Sales Value by Country (%), 2024 VS 2031
- 5.6 Asia Pacific
- 5.6.1 Asia Pacific Hirudin Sales Value, 2020-2031
- 5.6.2 Asia Pacific Hirudin Sales Value by Region (%), 2024 VS 2031
- 5.7 South America
- 5.7.1 South America Hirudin Sales Value, 2020-2031
- 5.7.2 South America Hirudin Sales Value by Country (%), 2024 VS 2031
- 5.8 Middle East & Africa
- 5.8.1 Middle East & Africa Hirudin Sales Value, 2020-2031
- 5.8.2 Middle East & Africa Hirudin Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Hirudin Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Hirudin Sales Value and Sales Volume
- 6.2.1 Key Countries/Regions Hirudin Sales Value, 2020-2031
- 6.2.2 Key Countries/Regions Hirudin Sales Volume, 2020-2031
- 6.3 United States
- 6.3.1 United States Hirudin Sales Value, 2020-2031
- 6.3.2 United States Hirudin Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Hirudin Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Hirudin Sales Value, 2020-2031
- 6.4.2 Europe Hirudin Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Hirudin Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Hirudin Sales Value, 2020-2031
- 6.5.2 China Hirudin Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Hirudin Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Hirudin Sales Value, 2020-2031
- 6.6.2 Japan Hirudin Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Hirudin Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Hirudin Sales Value, 2020-2031
- 6.7.2 South Korea Hirudin Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Hirudin Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Hirudin Sales Value, 2020-2031
- 6.8.2 Southeast Asia Hirudin Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Hirudin Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Hirudin Sales Value, 2020-2031
- 6.9.2 India Hirudin Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Hirudin Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Novartis
- 7.1.1 Novartis Company Information
- 7.1.2 Novartis Introduction and Business Overview
- 7.1.3 Novartis Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Novartis Hirudin Product Offerings
- 7.1.5 Novartis Recent Development
- 7.2 Teva Pharmaceuticals
- 7.2.1 Teva Pharmaceuticals Company Information
- 7.2.2 Teva Pharmaceuticals Introduction and Business Overview
- 7.2.3 Teva Pharmaceuticals Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Teva Pharmaceuticals Hirudin Product Offerings
- 7.2.5 Teva Pharmaceuticals Recent Development
- 7.3 Pfizer, Inc
- 7.3.1 Pfizer, Inc Company Information
- 7.3.2 Pfizer, Inc Introduction and Business Overview
- 7.3.3 Pfizer, Inc Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Pfizer, Inc Hirudin Product Offerings
- 7.3.5 Pfizer, Inc Recent Development
- 7.4 Pentapharm
- 7.4.1 Pentapharm Company Information
- 7.4.2 Pentapharm Introduction and Business Overview
- 7.4.3 Pentapharm Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Pentapharm Hirudin Product Offerings
- 7.4.5 Pentapharm Recent Development
- 7.5 DUOPUTAI
- 7.5.1 DUOPUTAI Company Information
- 7.5.2 DUOPUTAI Introduction and Business Overview
- 7.5.3 DUOPUTAI Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 DUOPUTAI Hirudin Product Offerings
- 7.5.5 DUOPUTAI Recent Development
- 7.6 Abbott
- 7.6.1 Abbott Company Information
- 7.6.2 Abbott Introduction and Business Overview
- 7.6.3 Abbott Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Abbott Hirudin Product Offerings
- 7.6.5 Abbott Recent Development
- 7.7 Keyken
- 7.7.1 Keyken Company Information
- 7.7.2 Keyken Introduction and Business Overview
- 7.7.3 Keyken Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Keyken Hirudin Product Offerings
- 7.7.5 Keyken Recent Development
- 7.8 Minapharm
- 7.8.1 Minapharm Company Information
- 7.8.2 Minapharm Introduction and Business Overview
- 7.8.3 Minapharm Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Minapharm Hirudin Product Offerings
- 7.8.5 Minapharm Recent Development
- 7.9 Salubris Bio
- 7.9.1 Salubris Bio Company Information
- 7.9.2 Salubris Bio Introduction and Business Overview
- 7.9.3 Salubris Bio Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Salubris Bio Hirudin Product Offerings
- 7.9.5 Salubris Bio Recent Development
- 7.10 Hoechst AG
- 7.10.1 Hoechst AG Company Information
- 7.10.2 Hoechst AG Introduction and Business Overview
- 7.10.3 Hoechst AG Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Hoechst AG Hirudin Product Offerings
- 7.10.5 Hoechst AG Recent Development
- 7.11 Ciba-Geigy
- 7.11.1 Ciba-Geigy Company Information
- 7.11.2 Ciba-Geigy Introduction and Business Overview
- 7.11.3 Ciba-Geigy Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 Ciba-Geigy Hirudin Product Offerings
- 7.11.5 Ciba-Geigy Recent Development
- 7.12 Boehringer Ingelheim
- 7.12.1 Boehringer Ingelheim Company Information
- 7.12.2 Boehringer Ingelheim Introduction and Business Overview
- 7.12.3 Boehringer Ingelheim Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Boehringer Ingelheim Hirudin Product Offerings
- 7.12.5 Boehringer Ingelheim Recent Development
- 7.13 Sanofi
- 7.13.1 Sanofi Company Information
- 7.13.2 Sanofi Introduction and Business Overview
- 7.13.3 Sanofi Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Sanofi Hirudin Product Offerings
- 7.13.5 Sanofi Recent Development
- 7.14 Xellia Pharmaceuticals
- 7.14.1 Xellia Pharmaceuticals Company Information
- 7.14.2 Xellia Pharmaceuticals Introduction and Business Overview
- 7.14.3 Xellia Pharmaceuticals Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.14.4 Xellia Pharmaceuticals Hirudin Product Offerings
- 7.14.5 Xellia Pharmaceuticals Recent Development
- 7.15 Haplogen Pharmaceuticals
- 7.15.1 Haplogen Pharmaceuticals Company Information
- 7.15.2 Haplogen Pharmaceuticals Introduction and Business Overview
- 7.15.3 Haplogen Pharmaceuticals Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.15.4 Haplogen Pharmaceuticals Hirudin Product Offerings
- 7.15.5 Haplogen Pharmaceuticals Recent Development
- 7.16 Shenzhen Kangtai Biological
- 7.16.1 Shenzhen Kangtai Biological Company Information
- 7.16.2 Shenzhen Kangtai Biological Introduction and Business Overview
- 7.16.3 Shenzhen Kangtai Biological Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.16.4 Shenzhen Kangtai Biological Hirudin Product Offerings
- 7.16.5 Shenzhen Kangtai Biological Recent Development
- 7.17 Dong-A ST
- 7.17.1 Dong-A ST Company Information
- 7.17.2 Dong-A ST Introduction and Business Overview
- 7.17.3 Dong-A ST Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.17.4 Dong-A ST Hirudin Product Offerings
- 7.17.5 Dong-A ST Recent Development
8 Industry Chain Analysis
- 8.1 Hirudin Industrial Chain
- 8.2 Hirudin Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Hirudin Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Hirudin Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
